PRLD today
$3.52-$0.26 (-6.88%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $4.03
Key levels
Resistance$4.25
Resistance$3.72
Support$3.34
Support$3.01
Latest news & SEC filings
EarningsPrelude Therapeutics to report Q3 2026 earnings
DealPrelude Therapeutics signs clinical trial supply deal with Eli Lilly
AnalystJP Morgan starts Prelude Therapeutics coverage with Overweight rating, $12 price target
All PRLD news →About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule therapies for cancer. Its pipeline targets areas such as hematologic malignancies and solid tumors, with drug candidates designed to address specific molecular pathways. The company's customers are primarily patients and healthcare providers participating in its clinical trials. It operates mainly in the United States.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
Prelude Therapeutics Inc (PRLD)
What Is the Price Target for PRLD?
SEPT Low Target
$8.00
SEPT Mid Target
$8.50
SEPT High Target
$12.00
Analyst Consensus
$8.50
Is PRLD a Buy or Sell Right Now?
Thesis
- •Revenue growing 73.4% YoY with UNKNOWN trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PRLD.
Start Free Trial →Is PRLD Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.24
4
Moat Score
NONE
3/9
Piotroski Score
-6.2
Altman Z-Score
What Is Smart Money Doing with PRLD?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PRLD Growth Story
Revenue YoY
73.4%
3yr Revenue CAGR
N/A%
EPS Growth YoY
23.21%
FCF Growth YoY
45.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for PRLD
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PRLD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:22 | $3.52 | 1,305 | $$5K | SELL |
| 20:54:14 | $3.52 | 1,000 | $$4K | MIDPOINT |
| 20:53:39 | $3.52 | 1,000 | $$4K | BUY |
| 20:34:58 | $3.54 | 1,400 | $$5K | MIDPOINT |
| 20:32:47 | $3.54 | 2,562 | $$9K | BUY |
5 dark pool trades shown · $$26K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Prelude Therapeutics Inc (PRLD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PRLD — frequently asked questions
What is PRLD stock price today?
Prelude Therapeutics Inc (PRLD) is at $3.52, down 6.88% (-$0.26) at the Nov 12, 2026 close.
Why is PRLD stock moving today?
Latest PRLD news — Nov 5, 2026: Prelude Therapeutics to report Q3 2026 earnings · Oct 13, 2026: Prelude Therapeutics signs clinical trial supply deal with Eli Lilly
What is the PRLD price target?
The average analyst price target for PRLD is $8.50, ranging from $8 to $12, based on 4 analysts. Latest: JP Morgan initiates on Sep 17, 2026.
What do analysts rate PRLD?
Analyst ratings for PRLD: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did PRLD beat earnings?
PRLD last reported on Aug 11, 2026: EPS -$0.14 vs -$0.20 expected — a beat of 28.8%.
Does PRLD pay a dividend?
PRLD does not currently pay a dividend.
What are PRLD support and resistance levels?
Support: $3.34, $3.01, $2.54. Resistance: $3.72, $4.25, $4.91.
What are insiders doing with PRLD?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on PRLD?
Nov 5, 2026: Prelude Therapeutics to report Q3 2026 earnings · Oct 13, 2026: Prelude Therapeutics signs clinical trial supply deal with Eli Lilly · Sep 17, 2026: JP Morgan starts Prelude Therapeutics coverage with Overweight rating, $12 price target